Cassava Sciences, Inc. (SAVA)
NASDAQ: SAVA · Real-Time Price · USD
1.660
0.00 (0.00%)
Apr 24, 2025, 4:00 PM EDT - Market closed
Company Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases.
Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.
Cassava Sciences, Inc. was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019.
The company was incorporated in 1998 and is based in Austin, Texas.
Cassava Sciences, Inc.
| Country | United States |
| Founded | 1998 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 30 |
| CEO | Richard Barry |
Contact Details
Address: 6801 N. Capital of Texas Highway, Suite 300 Austin, Texas 78731 United States | |
| Phone | 512-501-2444 |
| Website | cassavasciences.com |
Stock Details
| Ticker Symbol | SAVA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001069530 |
| CUSIP Number | 14817C107 |
| ISIN Number | US14817C1071 |
| Employer ID | 91-1911336 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Richard Jon Barry | Chief Executive Officer, President and Director |
| Eric J. Schoen | Chief Financial Officer |
| Dr. James W. Kupiec M.D. | Chief Medical Officer |
| Dr. George Thornton Ph.D. | Senior Vice President of Technology |
| R. Christopher Cook J.D. | Senior Vice President, Company Secretary and General Counsel |
| Michael Zamloot | Senior Vice President of Technical Operations |
| Dr. Michael Marsman Pharm.D. | Senior Vice President of Regulatory Affairs |
| Freda Nassif | Chief Business Officer and Chief Commercial Officer |
| Jaren Landen | Chief Clinical Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 21, 2025 | 8-K | Current Report |
| Apr 14, 2025 | ARS | Filing |
| Apr 14, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 3, 2025 | PRE 14A | Other preliminary proxy statements |
| Mar 25, 2025 | 8-K | Current Report |
| Mar 11, 2025 | 8-K | Current Report |
| Mar 3, 2025 | 10-K | Annual Report |
| Mar 3, 2025 | 8-K | Current Report |
| Feb 27, 2025 | 8-K | Current Report |
| Jan 7, 2025 | 8-K | Current Report |